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International Validation of the Low Anterior Resection
Syndrome Score
Therese Juul, MHSc,∗ Madelene Ahlberg, MHSc,‡ Sebastiano Biondo, MD, PhD,†
Katrine Jøssing Emmertsen, MD,∗ Eloy Espin, MD, PhD,§ Luis Miguel Jimenez, MD,§ Klaus E. Matzel, MD, PhD,‖
Gabriella Palmer, MD, PhD,‡ Anna Sauermann, MD,‖ Loris Trenti, MD,† Wei Zhang, MD,‖
Søren Laurberg, MD, PhD,∗ and Peter Christensen, MD, PhD, DMSc∗
Objective: The aims of this study were to investigate the convergent and
discriminative validity and reliability of the low anterior resection syndrome
(LARS) score in an international setting.
Background: The LARS score is a simple self-administered questionnaire
measuring bowel dysfunction after rectal cancer surgery. The score is intended
to be commonly used in international research and clinical practice in the
future. Therefore, a thorough validation in an international setting is of utmost
importance.
Methods: The LARS score was translated using methods in keeping with
current international recommendations. A total of 801 patients operated for
rectal cancer in Sweden, Spain, Germany, and Denmark completed the LARS
score questionnaire, including an anchor question assessing the impact of
bowel function on quality of life. A subgroup of 218 patients completed the
LARS score twice. Data were analyzed per country.
Results: The LARS score has demonstrated a high convergent validity in
terms of a high correlation between LARS score and quality of life (P <
0.001). Sensitivity ranged from 67.7% to 88.3% and specificity from 58.1%
to 86.3%. The LARS score was able to discriminate between groups of patients
differing with regard to radiotherapy, surgery, and age (P < 0.05). The score
also demonstrated high reliability at test-retest with narrow limits of agreement
and no statistically significant difference between scores at the first and second
test.
Conclusions: The Swedish, Spanish, German, and Danish versions of the
LARS score have proven to be valid and reliable tools for measuring LARS
in European rectal cancer patients.
Keywords: bowel dysfunction, functional outcome, low anterior resection
syndrome score, rectal neoplasms, validation
(Ann Surg 2014;259:728–734)
U p to 60% of rectal cancer patients undergoing low anterior re-section (LAR) suffer from bowel dysfunction, severely affecting
their quality of life (QoL).1–4 The complex of symptoms consist-
ing of incontinence for flatus and/or feces, urgency, constipation,
fragmentation, and frequent bowel movements is referred to as the
low anterior resection syndrome (LARS). Several studies have ad-
dressed the symptoms of LARS after rectal cancer, but a significant
variability exists in the reporting of outcomes after anterior resection.
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In a systematic review of 48 studies of long-term functional outcomes
after anterior resection for rectal cancer, the authors reported that 65%
of the studies did not use a validated assessment tool. Hence, the in-
tended meta-analysis was limited by the significant heterogeneity of
the primary data.1
To facilitate the monitoring of relevant functional LAR out-
comes in daily clinical practice and in clinical trials, a uniform termi-
nology and a common international tool for measuring bowel function
after LAR are required. This realization has led to the development
of a simple self-administered scoring system assessing the severity
of LARS—the LARS score (Fig. 1). The LARS score measures the
most important aspects of LARS, and the selection of the 5 included
items was primarily based on patients’ perceptions of the influence
of bowel function on QoL—and not merely on the opinions of pro-
fessionals. The development and validation of the LARS score in
a Danish population has been published by Emmertsen et al.5 The
Danish validation was based on a 27-item questionnaire, from which
the LARS score was developed. However, the current version of the
LARS score consisting of 5 items has not yet been validated.
As cultural and linguistic differences may affect the equiva-
lence of various language versions of the LARS score, it is crucial
that the score is translated according to current international recom-
mendations and that the validation is carried out in an international
setting. To cover the major part of Europe, this study includes a
Spanish (SPA) population to represent the southern part of Europe, a
German (GER) population to represent Central Europe, and a Swedish
(SWE)/Danish (DEN) population to represent the northern part of
Europe.
The main aims of this study were to investigate convergent
and discriminative validity and to explore the test-retest reliability
of the translated versions of the LARS score in several European
populations of rectal cancer patients.
METHODS
Translation
The original Danish version of the LARS score was initially
translated to English and subsequently from English to Swedish,
Spanish, and German. The translations to each language were done by
2 independent professional translators whose mother tongue was the
target language. The translators discussed any discrepancies between
the 2 versions until a final consensus was reached. A common version
was then established, and this version was back-translated to the orig-
inal language by a third independent translator whose mother tongue
was the language of the original version. The third translator, doing
the back-translation, was not familiar with the original version. The
back-translations were done to check whether the original meaning
of each question was preserved. The translations aimed at conceptual
equivalence rather than a word-for-word translation and the process
followed the recommendations of the WHO and the European Or-
ganisation for Research and Treatment of Cancer (EORTC).6–8 The
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FIGURE 1. LARS score questionnaire.
selected translators were not healthcare professionals, but the final
versions were checked and accepted by the investigators at each of
the participating centers.
Participants
Patients operated for rectal cancer from Sweden, Spain,
Germany, and Denmark and who were 18 years old or above were
included. All the participants had undergone either a curative total
mesorectal excision (TME) or a curative partial mesorectal excision
(PME) for rectal cancer in the period from 1st January 2001 to 31st
December 2009.
Exclusion criteria included the presence of stoma and/or known
disseminated or recurrent disease. For the purposes of this study, all
included patients are referred to as participants.
Participants were identified through local and national
databases by the local investigators at each of the participating cen-
ters. Subjects to be approached were selected randomly from the
pool of eligible subjects. Demographic and clinical information was
obtained from databases.
Participants were approached during the period extending from
1st March 2011 to 1st April 2012 to ensure a minimum duration of
14 months after surgery to allow their bowel function to have regained
stability.2,9 At the outset, it was decided to include more patients in
Spain due to historically low response rates to questionnaires.
Questionnaire
All participants were sent the LARS score questionnaire
(Fig. 1) along with an invitation to participate in the study. In ad-
dition, a separate question to assess their QoL (“Overall, how much
does your bowel function affects your quality of life?”) was sent with
the LARS score questionnaire. The available responses were “Not
at all”/“A little”/“Some”/ “A lot.” This extra question was added for
validation purposes only, to enable the investigation of the association
between LARS score and QoL.
Test-retest
To examine the test-retest reliability of the score, a randomly
selected subgroup of participants was mailed the LARS score ques-
tionnaire twice. The second test was mailed to the participants 1–2
weeks after the completion of the first test. If the time interval between
the completions of the 2 tests was outside the predefined interval of
1–9 weeks, data were excluded from the analysis. As a test-retest
analysis is only relevant if the subject of interest is stable, partici-
pants were explicitly asked if they had experienced any significant
change in bowel function between the first and the second test.10 Par-
ticipants confirming a change in bowel function were excluded from
the test-retest analysis. Nonresponders were further contacted once,
either by mail or by phone.
Statistical Analysis
The LARS score was computed and categorized into 3 groups:
no LARS (0–20 points), minor LARS (21–29 points), or major LARS
(30–42 points), according to the guidelines.5 To facilitate the analysis
of convergent validity, ie, the association between the LARS score
and QoL, participants were further categorized into 3 “QoL groups”:
no, minor, or some/major impact of bowel function on QoL.
The association between the LARS score and QoL was il-
lustrated by means of tables depicting the percentage of perfect fit,
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moderate fit, and no fit between the LARS group and the QoL group.
It was considered a perfect fit if both the patient perception of QoL
and the LARS score matched completely (eg, “No LARS/No impact
on QoL”). A mismatch in 1 category was deemed moderate fit and a
total mismatch was regarded as no fit.
Discriminative validity was evaluated by means of compar-
isons of groups expected to differ with regard to LARS: +/– radio-
therapy, type of surgery (TME/PME), and age older or younger than
the median age of the study population, ie, 68.8 years.
The sensitivity and specificity for identifying patients with
some/major impact on QoL with a cutoff at 30 points at the LARS
score scale were computed and reflect the ability of the LARS score
to predict impact of bowel function on QoL.
In the analysis of the test-retest reliability, the extent of agree-
ment between the numerical value of the LARS score at the first and
second test was demonstrated on a Bland Altman plot with limits
of agreement. The correlation between the numerical value of the
LARS score at the first and second test was assessed by intraclass
correlation coefficient. The difference between the numerical value
of the LARS score at the 2 tests was tested by means of the Student
t test. Furthermore, for each of the 5 individual questions of the
score, the agreement between the first and second response was ex-
plored by means of computing the percentage of perfect, moderate,
and no agreement. A perfect agreement was assigned when partici-
pants ticked off exactly the same category at the first and second test,
moderate agreement was assigned when responses differed by only
1 category, and no agreement was assigned when responses differed
by 2 or 3 categories at the 2 tests.
Radio- and chemotherapy were treated as dichotomous vari-
ables: no treatment at all versus treatment before and/or after surgery.
Age was both treated as a continuous variable and dichotomized to
younger or older than the median age of the total study population
(68.8 years).
Differences were tested per country by means of the Student t
test, χ 2 test, Kruskall-Wallis test, or Wilcoxon rank-sum test, depen-
dent on data type and distribution. All P values < 0.05 are considered
statistically significant. All statistical analyses were performed using
STATA 11 (StataCorp LP, College Station, TX).
Ethics
The study was approved by the local ethics committees in all
participating centers.
RESULTS
Translation
The double-forward translations revealed only minor discrep-
ancies, which were easily solved by discussion between the transla-
tors. All backward translations confirmed that the original meaning
of each of the 5 questions was retained. Investigators at each of the
participating centers accepted the final version of the LARS score.
Only 1 minor correction was proposed by the Swedish investigators
concerning the translation of “liquid stool.”
Participants
A total of 1073 patients were initially approached. Twelve were
excluded: 8 recently had a stoma and 4 had a recurrence, leaving 1061
approached patients eligible for the study. Out of the 1061 eligible
patients, 810 responded, and only 9 of those returned incomplete
questionnaires (completion rate 98.9%). Thus, 801 of the 1061 ap-
proached and eligible patients were included in the statistical analysis
(75.5%); see Table 1 for results per country. Clinical and demographic
data are shown in Table 2. Out of the 343 subjects initially approached
in the test-retest part of the study, 240 responded (70%). Eleven were
subsequently excluded because they reported a significant change in
bowel function between tests, and another 11 were excluded due to a
time period between tests outside of the predefined acceptable period
of 1–9 weeks. Thus, a total of 218 subjects were included in the test-
retest analysis [Sweden: n = 48, Spain: n = 59, Germany: n = 49,
Denmark: n = 62].
Responders versus Nonresponders
There was no statistically significant difference between re-
sponders and nonresponders in any country with regard to gender,
type of surgery, or radio- or chemotherapy. However, in Spain, the
responders were on average 3.5 years [95% confidence interval (CI):
1.1–5.8] younger than the nonresponders (P < 0.01), and a lower
proportion of Spanish responders were classified T3–T4 with a risk
difference of 13.7% (95% CI: 3.0–24.5) and P = 0.02. Also, tumor
level was on average 1.2 cm (95% CI: 0.01–2.3) higher in Danish
nonresponders compared with Danish responders (P= 0.05). No dif-
ference was found with regard to age, tumor (T) stage, or tumor level
in the remaining countries.
Convergent Validity
Table 3 shows a comparison between the calculated LARS
scores and the self-reported impact of bowel function on QoL for
participants in all the countries. Furthermore, the percentages of per-
fect, moderate, and no fit between the LARS group and the QoL
group for each country are summarized in Table 4. It is clear that “no
fit” was found in 4.3% in Swedish data, 6.0% in Spanish data, 7.7%
in German data, and 2.3% in Danish data.
Boxplots illustrating the association between the numerical
LARS score value and the QoL group are displayed in Figure 2. In all
countries, there was a statistically significant difference in the LARS
score between the 3 QoL groups (P< 0.001), ie, the higher the LARS
score, the more the impact of bowel function on QoL.
The sensitivity (95% CI) of the LARS score was: Sweden:
81.9% (76.4–87.4), Spain: 77.9% (71.9–83.9), Germany: 67.7%
(61.4–74.1), and Denmark: 88.3% (84.0–92.6).
The specificity (95% CI) of the LARS score was:
Sweden: 58.15 (51.0–65.2), Spain: 78.6% (72.6–84.5), Germany:
86.3% (81.6–90.9), and Denmark: 75.9% (70.2–81.6).
Discriminative Validity
In all countries, patients receiving radiotherapy had a statis-
tically significant higher LARS score than those who did not (P <
0.01), and patients who had undergone a TME operation had a statis-
tically significant higher LARS score than those who had undergone
a PME operation (P < 0.01). Patients below the median age of the
study population (68.8 years) had a statistically significant higher
LARS score compared with those who were older, with P values of
0.03 in Sweden, Spain, and Germany and of <0.001 in Denmark.
Differences between groups are demonstrated in Figure 3.
Test-Retest Reliability
Median (range) days between the first and the second test were
21 (15–42) days in Sweden, 23 (11–61) days in Spain, 18 (8–63) days
in Germany, and 16 (12–48) days in Denmark.
Figure 4 shows the agreement between the first and the second
numerical value of the LARS score by means of a Bland Altman plot.
The 95% limits of agreement were –8.2 to 7.9 in Sweden, –8.6 to 10.4
in Spain, –7.6 to 10.0 in Germany, and –13.8 to 13.0 in Denmark.
Intraclass correlation coefficients were 0.94, 0.92, 0.93, and 0.86
in Sweden, Spain, Germany, and Denmark, respectively. There was
no systematic difference in the LARS score at the first and second
test in Sweden (P = 0.85), in Spain (P = 0.18), in Germany (P =
0.08), or in Denmark (P = 0.66), ie, there was no tendency toward
Copyright © 2013 Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
730 | www.annalsofsurgery.com C© 2013 Lippincott Williams & Wilkins
Annals of Surgery  Volume 259, Number 4, April 2014 Low Anterior Resection Syndrome Score
TABLE 1. Patient Inclusion
Country Approached Responders Nonresponders Excluded Responders∗ Included in Analysis
Sweden 243 188 55 0 188 (77.4%)
Spain 329 190 139 4 186 (56.5%)
Germany 242 211 31 3 208 (86.0%)
Denmark 247 221 26 2 219 (88.7%)
Total 1061 810 251 9 801 (75.5%)
∗Excluded because of incomplete questionnaires.
TABLE 2. Clinical and Demographic Information
Sweden Spain Germany Denmark
No. participants 188 186 208 219
Males, n (%) 96 (51.1) 125 (67.2) 129 (62.0) 92 (42.0)
Age in years at time of survey, mean (SD) 67.9 (10.0) 67.2 (10.2) 65.7 (9.9) 70.2 (9.5)
Tumor stage
T0–T2, n (%) 98 (52.1) 101(54.3) 149 (71.6) 79 (44.1)
T3–T4, n (%) 90 (47.9) 85 (45.7) 59 (28.4) 100 (55.9)∗
Years since operation, mean (SD) 5.2 (2.4) 4.2 (1.9) 5.9 (2.1) 6.9 (1.7)
Type of surgery
TME, n (%) 170 (90.4) 135 (72.6) 166 (79.8) 132 (60.3)
PME, n (%) 18 (9.6) 51 (27.4) 42 (20.2) 87 (39.7)
Tumor level in cm, mean (SD) 9.9 (3.0) 9.3 (3.3) 8.7 (3.5) 10.2 (3.0)†
Radiotherapy, n (%) 144 (76.6) 131 (70.4) 114 (54.8) 43 (19.6)
Chemotherapy, n (%) 50 (26.6) 150 (80.7) 116 (55.8) 34 (15.5)
∗Forty missing (operated before the implementation of TNM classification in the Danish Colorectal Cancer Group
database).
†Two missing.
TABLE 3. Fit Between the QoL Group and LARS the
Score Group
Impact of Bowel
Function on QoL
No LARS
(0–20 Points)
Minor LARS
(21–29 Points)
Major LARS
(30–42 Points)
SWE (n = 188)
No 19 (10.1%) 1 (0.5%) 2 (1.0%)
Minor 17 (9.0%) 24 (12.8%) 42 (22.3%)
Some/major 6 (3.2%) 9 (4.8%) 68 (36.2%)
SPA (n = 183)
No 16 (8.7%) 9 (4.9%) 4 (2.2%)
Minor 18 (9.8%) 12 (6.6%) 11 (6.0%)
Some/major 7 (3.8%) 18 (9.8%) 88 (48.1%)
GER (n = 207)
No 22 (10.6%) 1 (0.5%) 1 (0.5%)
Minor 31 (15.0%) 15 (7.3%) 10 (4.8%)
Some/major 15 (7.3%) 26 (12.6%) 86 (41.6%)
DEN (n = 218)
No 41 (18.8%) 9 (4.1%) 3 (1.4%)
Minor 33 (15.1%) 24 (11.0%) 31 (14.2%)
Some/major 2 (0.9%) 7 (3.2%) 68 (31.2%)
scoring either higher or lower at the second test compared with the
first.
Results of the investigation of the agreement between the an-
swers at the first and second test in each of the 5 individual items
of the score are displayed in Table 5. “No agreement,” ie, responses
differed for more than 2 categories at the 2 tests, was nonexisting
in German data, and was found only in 2.1% in question 2 in the
Swedish data. The proportion of “no agreement” was also very low
in Spanish and Danish data, ranging from 1.6% to 6.9%.
TABLE 4. Fit Between the LARS Score Group and the
QoL Group
SWE (n = 188)
Perfect fit 59.0 (51.7–66.1)
Moderate fit 36.7 (29.8–44.0)
No fit 4.3 (1.9–8.2)
SPA (n = 183)
Perfect fit 63.4 (56.0–70.4)
Moderate fit 30.6 (24.0–37.8)
No fit 6.0 (3.0–10.5)
GER (n = 207)
Perfect fit 59.4 (52.4–66.2)
Moderate fit 32.9 (26.5–39.7)
No fit 7.7 (4.5–12.2)
DEN (n = 218)
Perfect fit 61.0 (54.2–67.5)
Moderate fit 36.7 (30.3–43.5)
No fit 2.3 (0.7–5.3)
Values are in percentages with exact 95% CI.
DISCUSSION
This study has validated the LARS score (Fig. 1) in 4 popula-
tions of rectal cancer patients across Europe. The score has proven to
be easily translated and has demonstrated convincing psychometric
properties regarding convergent validity, discriminative validity, and
reliability.
When developing international tools, semantic equivalence be-
tween different language versions is crucial. Therefore, the LARS
score was translated using meticulous methods in accordance with
current international recommendations.6,7 The objective nature of all
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5 items of the score, in combination with simple and straightforward
phrasing, simplified the process of translation and no difficulties were
met. Hence, the English, Swedish, Spanish, German, and Danish ver-
sions of the LARS score can be considered semantically equivalent.
This study clearly demonstrates that the LARS score is accu-
rately associated with self-reported QoL in all 4 participating coun-
tries. High proportions of perfect and moderate fit between the LARS
group and the QoL group were found (Table 4), and the numerical
value of the LARS score was significantly higher with increasing
levels of impact of bowel function on QoL (Fig. 2). Sensitivity and
specificity were high in most countries, ie, the LARS score was, to
a great extent, able to predict the patients’ self-reported impact of
bowel function on QoL. It should be noted that a 100% sensitivity/
specificity is not desirable, because this would indicate that LARS
and QoL are exactly the same thing. Nevertheless, the German
sensitivity and the Swedish specificity were somewhat lower than
those of the other countries. Given the meticulous translation proce-
dure, this disparity is probably not due to a lack of semantic equiv-
alence between the various language versions of the LARS score. A
true difference in the association between LARS and QoL in different
FIGURE 2. Boxplot showing the relationship between the LARS
score and the QoL group per country. In all countries, the dif-
ferences in LARS scores between the QoL groups were statisti-
cally significant (P < 0.001).
cultures cannot be ruled out, but a more plausible explanation is a
cross-cultural difference in how patients interpret the QoL question.
An investigation of the LARS score’s correlation to a validated mea-
sure of QoL would help in clarifying this. Therefore, we are currently
working on examining the relationship between the LARS score and
the EORTC QLQ-C30.11
Apart from the abovementioned deviation/discrepancy, the re-
sults are comparable to the ones published by Emmertsen et al.5 The
findings are important, because a high association between the LARS
score and the self-reported impact of bowel function on QoL was a
prerequisite for items to be selected for the score during the process
of development. This requirement was introduced because the au-
thors wished to develop a score based predominantly on the patient’s
perspectives rather than solely on the opinions of professionals.
The applicability of the LARS score would be limited without
the ability to discriminate between subgroups known to differ in
terms of LARS. Therefore, we investigated this aspect concerning
radiotherapy, surgery, and age, and the results confirm that the score
is able to discriminate between groups (Fig. 3). Results on test-retest
reliability showed narrow limits of agreement and no statistically
significant differences between the numerical value of the LARS
score at the first and second test (Fig. 4). Furthermore very high
proportions of moderate and perfect agreement between answers at
FIGURE 4. Bland Altman plot (jittered) illustrating the differ-
ence between the numerical LARS score values at the first and
second test.
FIGURE 3. The LARS score in clinical subgroups: −/+ radiotherapy, type of surgery (PME/TME), and younger or older than the
median age of the study population (68.8 years). All differences were statistically significant (P < 0.05).
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TABLE 5. Agreement Between Response at the First and Second Tests for Each Question of the LARS Score
Agreement Sweden (n = 46–48) Spain (n = 56–58) Germany (n = 47–49) Denmark (n = 61–62)
Q. 1
Perfect 83.0 (69.2–92.4) 65.5 (51.9–77.5) 79.6 (65.7–89.8) 77.0 (64.5–86.8)
Moderate 17.0 (7.6–30.8) 27.6 (16.7–40.9) 20.4 (10.2–34.3) 16.4 (8.2–28.1)
No 0 (0–7.5)∗ 6.9 (1.9–16.7) 0 (0–7.3)∗ 6.6 (1.8–15.9)
Q. 2
Perfect 77.1 (62.7–88.0) 74.1 (61.0–84.7) 85.7 (72.8–94.1) 83.9 (72.3–92.0)
Moderate 20.8 (10.5–35.0) 24.1 (13.9–37.2) 14.3 (5.9–27.2) 12.9 (5.7–23.9)
No 2.1 (0.0–11.1) 1.7 (0.0–9.2) 0 (0–7.3)∗ 3.2 (0.4–11.2)
Q. 3
Perfect 69.6 (54.2–82.3) 82.1 (69.6–91.1) 89.4 (76.9–96.5) 80.6 (68.6–89.6)
Moderate 30.4 (17.7–45.8) 16.1 (7.6–28.3) 10.6 (3.5–23.1) 17.7 (9.2–29.5)
No 0 (0–7.7)∗ 1.8 (0.0–9.6) 0 (0–7.5)∗ 1.6 (0.0–8.7)
Q. 4
Perfect 76.1 (61.2–87.4) 72.4 (59.1–83.3) 80.9 (66.7–90.9) 72.6 (59.8–83.1)
Moderate 23.9 (12.6–38.8) 25.9 (15.3–39.0) 19.1 (9.1–33.3) 25.8 (15.5–38.5)
No 0 (0–7.7)∗ 1.7 (0.0–9.2) 0 (0–7.5)∗ 1.6 (0.0–8.7)
Q. 5
Perfect 87.5 (74.8–95.3) 72.4 (59.1–83.3) 85.7 (72.8–94.1) 71.0 (58.1–81.8)
Moderate 12.5 (4.7–25.2) 24.1 (13.9–37.2) 14.3 (5.9–27.2) 27.4 (16.9–40.2)
No 0 (0–7.4)∗ 3.4 (0.4–11.9) 0 (0–7.3)∗ 1.6 (0.0–8.7)
Values are in percentages with exact 95% CI.
∗One-sided 97.5% CI.
the first and second test in each of the 5 LARS score items were found
(Table 5).
The LARS score has, with a few exceptions, demonstrated
similar validity and reliability across countries, and these results do
furthermore correlate well with the results obtained in the origi-
nal validation in Danish patients.5 This confirms that the score per-
forms equally well in several European countries despite cultural
differences.
Response rates were high, and nonresponders were similar
to responders with regard to all available clinical and demographic
data in all countries except Spain. Even though the response rate
was somewhat lower in Spain, the theoretical risk of selection bias
is minimized by a final inclusion of participants with demographic
and clinical features similar to the other countries. The statistically
significant differences with regard to age and tumor stage between
Spanish responders and nonresponders can be considered clinically
irrelevant due to the small degree of difference. Therefore, we think
that our results apply well to the total populations of patients operated
for rectal cancer in all of the participating countries.
In the test-retest analysis, the interval between the tests ranged
up to 9 weeks. This long interval was chosen to decrease the risk
of participants copying their first set of answers for their second. A
potential disadvantage is an actual increase in numbers of patients
having a true change in bowel function. We minimized the risk by
excluding participants who reported a significant change in bowel
function between the tests.
There was a good compliance across all items with only <1%
missing values. Importantly, it demonstrates that the LARS score is
easy to understand and easy to complete.
During the last few decades, numerous instruments have been
described to assess bowel dysfunction. Nevertheless, in a recent sys-
tematic review, the quality of the majority of these instruments was
questioned due to the lack of proper psychometric validation.12 In the
review, frequently used scores, such as the Wexner fecal incontinence
score,13 Cleveland constipation score14, and St Marks incontinence
score15, were categorized as the lowest possible “grade C.” In this
study, we have attempted to address the crucial issue of validation
by adapting and following a robust and systematic approach to the
validation of the LARS score.
Future perspectives for the LARS score are, first, to investigate
and identify what constitutes a clinically relevant difference and to
explore sensitivity to change on the LARS score system. The next
step would be to compare the LARS score with validated QoL in-
struments such as EORTC QLQ-C30.11 Furthermore, we encourage
the translation of the LARS score to more languages, followed by a
validation, if the score is intended for use in cultures dissimilar to the
European culture.
Needless to say, validated universally acceptable assessment
tools are crucial for assessment of LARS. The LARS score offers a
quick, easy, and accurate option for measuring LARS in rectal can-
cer patients, and the current study has shown its applicability across
several European countries. Therefore, it has the potential of being
a valuable time-saving screening tool in clinical practice by effec-
tively identifying patients with LARS in need of further attention or
examination. Furthermore, the LARS score will be useful in clinical
research whenever LARS needs to be accurately quantified.
In this study, the LARS score was tested in a large group of
patients operated for rectal cancer, but because LARS arises from
surgery rather than from the cancer, the LARS score will also be
useful in groups of patients undergoing rectal surgery for reasons
other than cancer.
CONCLUSIONS
In conclusion, the English, Swedish, Spanish, German, and
Danish versions of the LARS score can be considered semantically
equivalent. The Swedish, Spanish, German, and Danish versions of
the LARS score have demonstrated high convergent and discrimina-
tive validity and reliability. We propose a systematic implementation
of the LARS score for both research and clinical purposes.
Addendum
The English version of the LARS score is shown in Figure 1 in
this article, and the Swedish, Spanish, German, and Danish versions
of the LARS score can be obtained by contacting the first author.
Copyright © 2013 Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
C© 2013 Lippincott Williams & Wilkins www.annalsofsurgery.com | 733
Juul et al Annals of Surgery  Volume 259, Number 4, April 2014
REFERENCES
1. Scheer AS, Boushey RP, Liang S, et al. The long-term gastrointestinal func-
tional outcomes following curative anterior resection in adults with rectal
cancer: a systematic review and meta-analysis. Dis Colon Rectum.
2011;54:1589–1597.
2. Emmertsen KJ, Laurberg S. Bowel dysfunction after treatment for rectal cancer.
Acta Oncol. 2008;47:994–1003.
3. Camilleri-Brennan J, Steele RJ. Quality of life after treatment for rectal cancer.
Br J Surg. 1998;85:1036–1043.
4. Camilleri-Brennan J, Steele RJ. Prospective analysis of quality of life and sur-
vival following mesorectal excision for rectal cancer.Br J Surg. 2001;88:1617–
1622.
5. Emmertsen KJ, Laurberg S. Low anterior resection syndrome score: develop-
ment and validation of a symptom-based scoring system for bowel dysfunc-
tion after low anterior resection for rectal cancer. Ann Surg. 2012;255:922–
928.
6. Dewolf L, Koller M, Velikova G, et al. EORTC Quality of
Life Group translation procedure. 2009. Available at: http://groups.
eortc.be/qol/downloads/translation manual 2009.pdf . Accessed June 15,
2012.
7. World Health Organization. Process of translation and adaptation of instru-
ments. 2010. Available at: http://www.who.int/substance abuse/research tools/
translation/en/. Accessed October 12, 2012.
8. Bullinger M, Alonso J, Apolone G, et al. Translating health status question-
naires and evaluating their quality: the IQOLA Project approach. International
Quality of Life Assessment. J Clin Epidemiol. 1998;51:913–923.
9. Neuman HB, Schrag D, Cabral C, et al., Can differences in bowel function
after surgery for rectal cancer be identified by the European Organization for
Research and Treatment of Cancer quality of life instrument? Ann Surg Oncol.
2007;14:1727–1734.
10. Streiner DL, Norman GR. Health Measurement Scales, a Practical Guide to
Their Development and Use. 4th ed. Oxford: Oxford University Press; 2008.
11. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for
Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for
use in international clinical trials in oncology. JNatl Cancer Inst. 1993;85:365–
376.
12. Emmanuel A, Chatoor D. Questionnaires to assess bowel function, In: Cardozo
L, ed. Textbook of Female Urology and Urogynecology. London: Informa
Healthcare; 2010:133–137.
13. Jorge JM, Wexner SD. Etiology and management of fecal incontinence. Dis
Colon Rectum. 1993;36:77–97.
14. Agachan F, Chen T, Pfeifer J, et al. A constipation scoring system to sim-
plify evaluation and management of constipated patients. Dis Colon Rectum.
1996;39:681–685.
15. Vaizey CJ, Carapeti E, Cahill JA, et al. Prospective comparison of faecal
incontinence grading systems. Gut. 1999;44:77–80.
Copyright © 2013 Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
734 | www.annalsofsurgery.com C© 2013 Lippincott Williams & Wilkins
